Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas
Findings from the EREMISS study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1647 results
FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC
Evidence for efficacy is based on the results from the PSMAfore study
EMA Recommends Extension of Indications for Pirtobrutinib
New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia
Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with Oesophageal Squamous Cell Cancer
Findings from a biomarker analysis from the RATIONALE-302 study
Potential for Larger Gene Panels to Increase the Number of Molecularly Matched Therapies in Patients with Advanced Solid Tumours
Findings from the ProfiLER-02 study
FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET
Evidence for efficacy is based on the results from the CABINET study
Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies
EMA Recommends Extension of Indications for Glofitamab
New indication concerns the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified who are ineligible for autologous stem cell transplant
Cancer Mortality Prediction for 2025 Continues to Show Favourable Trends In the EU
An up-to-date projection of cancer mortality patterns in the European Union
Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve Patients with Advanced or Metastatic Non-Clear Cell RCC
Findings from the SUNNIFORECAST study
Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for Treatment of Patients with Metastatic NSCLC
Findings from the 3475A-D77 study
FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1)
Evidence for efficacy is based on the results from the KEYNOTE-811 study